New Mexico INBRE investigator Dr. Kevin Houston has been awarded a $1 million, four-year grant from the National Institutes of Health (NIH) to investigate how GPER1-dependent mechanisms of tamoxifen action contribute to tamoxifen resistance in breast cancer cells.
The goal of this multiyear study entitled “GPER1-Dependent Regulation of IGF-1R in Tamoxifen Treated Breast Cancer Cells” is to further characterize how GPER1 is involved in the development of tamoxifen resistance in breast cancer cells and to identify potential targets for future design of pharmaceutical treatments that can lessen the likelihood that resistance will develop in breast cancer patients that are treated with tamoxifen.
In addition, this funding will provide the resources necessary to encourage and support both undergraduate and graduate students in research training while they are completing their studies at NMSU.